Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Encouraged To Spread Its Wings In Learn Phase of Adaptive Trials

Executive Summary

While FDA is granting industry a great deal of leeway in designing early, learn-phase adaptive trial models, the agency is suggesting that emphasis be placed on dose response and exposure risk, FDA officials indicated at a recent Pharmaceutical Research & Manufacturers of America workshop

You may also be interested in...



FDA Can Expand Access To Experimental Drugs, Without Compromising Trials

FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb

FDA Can Expand Access To Experimental Drugs, Without Compromising Trials

FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb

FDA Puts Hold On Adaptive Trials, Wants More Clarity On Basics

FDA would like to slow the escalating momentum behind adaptive clinical trial designs to allow time to craft better working definitions of the new models and build a better base before moving forward, agency officials indicated at a Pharmaceutical Research & Manufacturers of America workshop

Related Content

UsernamePublicRestriction

Register

PS047848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel